Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Literature DB >> 20539732

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Christopher G Azzoli¹, Giuseppe Giaccone, Sarah Temin.

Abstract

ASCO published a guideline on use of chemotherapy in advanced stage non-small-cell lung cancer in 1997. The latest update covers treatment with chemotherapy and biologic agents and reviews literature from 2002 to 2009.

Entities: Disease

Year: 2010 PMID： 20539732 PMCID： PMC2805345 DOI： 10.1200/JOP.091065

Source DB: PubMed Journal: J Oncol Pract ISSN： 1554-7477 Impact factor: 3.840

5 in total

Review 1. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Authors: David G Pfister; David H Johnson; Christopher G Azzoli; William Sause; Thomas J Smith; Sherman Baker; Jemi Olak; Diane Stover; John R Strawn; Andrew T Turrisi; Mark R Somerfield
Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544

2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.

Authors:
Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544

3. Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis.

Authors:
Journal: CADTH Technol Overv Date: 2010-03-01

4. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors: Christopher G Azzoli; Sarah Temin; Timothy Aliff; Sherman Baker; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; William Pao; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone
Journal: J Clin Oncol Date: 2011-09-06 Impact factor: 44.544

5. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245

5 in total

15 in total

1. Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients.

Authors: Dae Ho Lee; Chang-Min Choi; Sang-We Kim; Cheolwon Suh; Jung-Shin Lee
Journal: Med Oncol Date: 2011-04-16 Impact factor: 3.064

2. The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry.

Authors: Rob G Stirling; S M Evans; P McLaughlin; M Senthuren; J Millar; J Gooi; L Irving; P Mitchell; A Haydon; J Ruben; M Conron; T Leong; N Watkins; J J McNeil
Journal: Lung Date: 2014-06-08 Impact factor: 2.584

3. Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK -Positive Non-Small-Cell Lung Cancer.

Authors: Lisa A Raedler
Journal: Am Health Drug Benefits Date: 2015-03

4. Trends and Outcomes of Non-Small-Cell Lung Cancer in Omani Patients: Experience at a university hospital.

Authors: Muhammad Furrukh; Shiyam Kumar; Khawaja F Zahid; Hanan S Al-Shamly; Zainab A Al-Jabri; Ikram A Burney; Mansour S Al-Moundhri
Journal: Sultan Qaboos Univ Med J Date: 2017-10-10

5. Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer.

Authors: Alejandro Avilés-Salas; Saé Muñiz-Hernández; Héctor Aquiles Maldonado-Martínez; José G Chanona-Vilchis; Laura-Alejandra Ramírez-Tirado; Norma HernáNdez-Pedro; Rita Dorantes-Heredia; José Manuel RuíZ-Morales; Daniel Motola-Kuba; Oscar Arrieta
Journal: Oncol Lett Date: 2016-12-16 Impact factor: 2.967

6. Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.

Authors: Seung Hun Jang; Seong Yeol Kim; Joo Hee Kim; Sunghoon Park; Yong Il Hwang; Dong-Gyu Kim; Ki-Suck Jung
Journal: J Cancer Res Clin Oncol Date: 2012-11-04 Impact factor: 4.553